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The acquisition of reliable kinetic parameters for the characterization of biomolecular interactions is an
important component of the drug discovery and development process. While several benchmark studies
have explored the variability of kinetic rate constants obtained from multiple laboratories and bio-
sensors, a direct comparison of these instruments' performance has not been undertaken, and systematic
factors contributing to data variability from these systems have not been discussed. To address these
questions, a panel of ten high-afﬁnity monoclonal antibodies was simultaneously evaluated for their
binding kinetics against the same antigen on four biosensor platforms: GE Healthcare's Biacore T100,
Bio-Rad's ProteOn XPR36, ForteBio's Octet RED384, and Wasatch Microﬂuidics's IBIS MX96. We
compared the strengths and weaknesses of these systems and found that despite certain inherent sys-
tematic limitations in instrumentation, the rank orders of both the association and dissociation rate
constants were highly correlated between these instruments. Our results also revealed a trade-off be-
tween data reliability and sample throughput. Biacore T100, followed by ProteOn XPR36, exhibited
excellent data quality and consistency, whereas Octet RED384 and IBIS MX96 demonstrated high ﬂexi-
bility and throughput with compromises in data accuracy and reproducibility. Our results support the
need for a “ﬁt-for-purpose” approach in instrument selection for biosensor studies.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The characterization of antibody-antigen interactions is essen-
tial for the successful development of antibody-based therapeutics.
Label-free optical surface plasmon resonance (SPR) biosensors, the
gold standard for measuring the binding afﬁnity and kinetics of
molecular interactions, are used across multiple stages of drug
discovery and development [1e3]. SPR biosensors have been used
to characterize antibody-antigen interactions for approximately
two decades [4e6], with applications ranging from the low-
resolution afﬁnity screening of antibody supernatants [7], to thesurface plasmon resonance; BLI, B
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Inc. This is an open access article urigorous, high-resolution kinetic constant determinations of puri-
ﬁed antibodies [8], and the classiﬁcation of antibody binding epi-
topes via epitope binning studies [9]. The availability of high-
quality binding data enables the early selection of criteria-
meeting drug candidates and provides crucial information for
pharmacokinetic/pharmacodynamic modeling in the design of
clinical dosing strategies [10].
With the rapidly expanding use of monoclonal antibodies
(mAbs) and antibody-like scaffolds for various therapeutic in-
dications [11,12], the demand for the efﬁcient, rapid and accurate
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D. Yang et al. / Analytical Biochemistry 508 (2016) 78e96 79requirements has dramatically increased. During recent years, a
wide variety of innovative instruments have been developed to
address this increasing demand, many of which have demonstrated
signiﬁcant throughput improvements over the traditional Biacore
SPR platform [13]. These instruments differ in either the design of
microﬂuidic channel conﬁgurations and/or the optical principles in
the detection of bimolecular interactions. Examples include the
6  6 crisscross microﬂuidics conﬁguration in Bio-Rad's ProteOn
XPR36, the 96-microarray printing by the Continuous Flow
Microspotter (CFM) in Wasatch Microﬂuidics's IBIS MX96 [14,15],
and the BioLayer Interferometry (BLI) optical detection technique in
ForteBio's Octet RED384 [16] that is coupled to a 384-well high-
throughput format. While the well-established SPR-based (GE
Healthcare's Biacore T100 and Bio-Rad's ProteOn XPR36) and BLI-
based (ForteBio's Octet RED384) platforms are widely used by
many laboratories worldwide, the Wasatch Microﬂuidics's IBIS
MX96 instrument is relatively new to the biosensor ﬁeld. The IBIS
MX96 operates based on the SPR imaging (SPRi) sensor technology
that provides detection in spatial orientation e which the regular
SPR cannot, thus enabling multiplex imaging of ligand surfaces in
an array format [15]. Collectively, researchers now have a number
of instruments to choose from for their biosensor studies.
Although these various biosensor platforms all provide kinetic
data that is essential for characterizing molecular interactions, they
are costly investments. For new users with little hands-on
biosensor experience, the decision of which instrument to pur-
chase can often be a challenging task given the many factors to
consider, including data quality, performance consistency,
throughput, ease of operation, and material consumption, all of
which must often be balanced against cost. To ensure that users
select the instrument that can deliver the most reliable results for
the intended applications, it is important for them to be aware of
each instrument's strengths and weaknesses prior to purchase.
While past benchmark studies have explored the variability in re-
ported kinetic rate constants across laboratories and instruments
[8,17], a comprehensive comparison of the various biosensor plat-
forms has not been conducted.
With the availability of the four routinely used biosensor plat-
forms in our laboratory (the Biacore T100, ProteOn XPR36, Octet
RED384, and IBIS MX96), we performed a head-to-head compari-
son study using a panel of high-afﬁnity mouse-derived monoclonal
antibodies against human proprotein convertase substilisin kexin
type 9 (PCSK9). Our goals were to determine the effect of instru-
mental performance on data quality and variability, and to help
guide the selection of appropriate platforms for antibody-antigen
studies in drug discovery research. We compared the experi-
mental details of each instrument, from ligand surface uniformity
to analyte binding analysis, and discussed the strength and weak-
nesses of each biosensor platform with an emphasis on data con-
sistency, comparability, and operational efﬁciency.
Materials and methods
Proteins and antibodies
Suspension HEK293-6E cells were transfected with plasmid
DNA encoding C-terminally 6-His-tagged human PCSK9 using the
TransIT-PRO system (Mirus Bio LLC). The transfected cells were
incubated for 4 days, and then the mediumwas harvested and used
to purify the 6-His-tagged PCSK9 with a Ni-NTA His-Bind Super-
ﬂow column (Novagen) following the manufacturer's instructions.
CHO cells were transfectedwith plasmid DNAs containing heavy
chain and light chain cassettes using Freestyle CHO Expression
Medium with 8 mM Glutamax (Invitrogen). The transfected cells
were incubated for 7 days, and then themediumwas harvested andused to purify the antibodies with the €AKTA afﬁnity chromatog-
raphy system and MabSelect Sure resin (GE Healthcare) following
standard methods [18]. The puriﬁed mAbs were formulated in
60 mM sodium acetate (pH 5.0), and their concentrations were
determined by adsorption at 280 nm using an extinction coefﬁcient
of 1.36 [18] in NanoDrop™ 8000 Spectrophotometer (Thermo
Fischer Scientiﬁc). Their purities were subsequently assessed to be
>95% monomer by size exclusion ultra-performance liquid chro-
matography (UPLC) (ACQUITY, Waters Corporation).
Instruments and reagents
The binding experiments were performed on four biosensors,
the Biacore T100, ProteOn XPR36, Octet RED384, and IBIS MX96.
The Biacore T100, equipped with CM5 sensor chips, was purchased
from GE Healthcare (Piscataway, NJ, USA) and the ProteOn XPR36,
equipped with a GLM sensor chip, was purchased from Bio-Rad
(Hercules, CA, USA). The Octet RED384, equipped with AHC (anti-
Human IgG Fc capture) biosensor tips was purchased from ForteBio
(Menlo Park, CA, USA), and the IBIS MX96, supplied with a CFM
printer and SensEye COOH-G chip was purchased from Wasatch
Microﬂuidics (Salt Lake City, UT, USA). Recombinant protein A/G
was purchased from Thermo Fischer Scientiﬁc (catalog # 21186). To
couple the protein A/G to the biosensor surfaces, we used an amine
coupling kit consisting of 10 mM sodium acetate (pH 4.5), 200 mM
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC), 50 mM N-hydroxysuccinimide (NHS), and 1 M
ethanolamine-HCl (pH 8.5) (GE Healthcare, product # BR1000050)
and the ProteOn amine coupling kit containing 400 mM EDC,
100 mM N-hydroxysulfosuccinimide (sulfo-NHS), and 1 M
ethanolamine-HCl (pH 8.5) (Bio-Rad, catalog # 1762410). Various
regeneration solutions, including 4MMgCl2,10mM glycine-HCl pH
2.5, pH 2.0, and pH 1.5 (GE Healthcare), and 0.85% phosphoric acid
(Bio-Rad) stock diluted at 1/500 (v/v) in water were tested.
Biacore T100 kinetic measurements
Protein A/G was immobilized onto the 4 individual ﬂow cells in
the CM5 sensor chip using a standard coupling protocol. First, the
carboxyl groups on the sensor surface were activated by injecting a
fresh mixture of EDC/NHS (200 mM/50 mM), and then protein A/G
prepared at 30 mg/mL in sodium acetate (pH 4.5) was injected over
the activated surface, and the proteinwas covalently attached by its
primary amines. Finally, the excess reactive esters were blocked
with 1 M ethanolamine. Each step was performed with a 7-min
injection at a 5 ml/min ﬂow rate. For the subsequent antibody-
capturing step, the ﬂow rate was increased to 10 ml/min. Each
mAb, prepared at 0.063 mg/mL in HBS-EP (10 mM HEPES [pH 7.4],
150 mM NaCl, 3 mM EDTA, and 0.005% v/v polysorbate P20)
running buffer, was injected serially onto ﬂow cells 2, 3, and 4 using
programmed times of 220 s, 110 s, and 55 s, respectively. Flow cell 1
was left empty to provide a reference surface. To measure the
binding kinetics, human PCSK9 from 100 nM to 0.39 nM in 2-fold
serial dilutions, as well as a blank buffer for baseline subtraction
were injected sequentially with a regeneration step inserted be-
tween each cycle. Regeneration of the protein A/G surface was
achieved with two 18-sec pulses of glycine (pH 1.5) at 50 ml/min.
The binding interactions were monitored in running buffer over a
10-min association period and a 45-min dissociation period at
30 ml/min.
ProteOn XPR36 kinetic measurements
Similar coupling procedures were used to immobilize protein A/
G onto the GLM sensor chip imprinted with 6 crisscrossing ﬂow
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NHS was used in combination with 400 mM EDC. Each activation,
immobilization, and deactivation step was carried out for 5 min
with 6 parallel injections in the horizontal direction at 30 ml/min.
The prepared protein A/G surfaces were subsequently conditioned
with three 18-sec pulses of glycine (pH 1.5) at 100 ml/min in both
the horizontal and vertical directions. Two different mAbs, each
prepared at 0.25 mg/mL, 0.125 mg/mL, and 0.063 mg/mL in PBS-T-
EDTA (PBS [pH 7.4], 0.005% Tween-20, and 3 mM EDTA) running
buffer were then injected in parallel in the vertical direction for
160 s at 25 ml/min. Channels 1e3 were injected with one mAb, and
channels 4e6 were injected with the other. Following a switch in
orientation of the sensor chip and a blank buffer injection of 60 s,
the antigen binding kinetics of the mAbs in the six samples was
measured by injecting 5 concentrations of human PCSK9, together
with a blank buffer, simultaneously. Three different series of human
PCSK9 concentrations (100 nMe6.25 nM, 25 nMe1.56 nM, and
5 nMe0.313 nM) were prepared by 2-fold serial dilution. The
binding interactions were monitored in running buffer over a 10-
min association period and a 45-min dissociation period at 40 ml/
min. After each binding cycle, the protein A/G surface was regen-
erated with two 18-sec pulses of glycine (pH 1.5) at 100 ml/min in
both the horizontal and vertical directions.
Octet RED384 kinetic measurements
Each mAb prepared at 20 mg/mL, 10 mg/mL, and 5 mg/mL in
1  KB (PBS pH [7.4], 0.02% Tween-20, 0.1% albumin, and 0.05%
sodium azide) running buffer was dispensed into a 384-well tilted-
bottommicroplate at a volume of 90 ml per well. Each concentration
occupied 8 vertical wells. A second 384-well microplate containing
human PCSK9 at 7 titrated concentrations (100 nMe1.56 nM, in 2-
fold serial dilutions), the glycine [pH 1.5] regeneration solution, and
1  KB buffer for baseline stabilization was also prepared. Both
plates were agitated at 1000 rpm over the entire course of the
experiment. A total of 16 AHC (anti-human Fc capture) sensor tips
were used for a group of 2 mAbs (8 sensors each) per binding cycle.
Prior to the binding measurements, the sensor tips were pre-
hydrated in 1  KB for 5 min, followed by 3 cycles of pre-
conditioning with 15-sec dips in glycine (pH 1.5), alternating with
15-sec dips in 1  KB. The sensor tips were then transferred to the
mAb-containing wells for a 200-sec loading step. After a 60-sec
baseline dip in 1  KB, the binding kinetics were measured by
dipping the mAb-coated sensors into the wells containing human
PCSK9 at varying concentrations. The binding interactions were
monitored over a 500-sec association period and followed by a 30-
min dissociation period in newwells containing fresh 1 KB buffer.
The AHC sensor tips were regenerated with two 18-sec dips in
glycine (pH 1.5) between each binding cycle.
IBIS MX96 kinetic measurements
Multi-cycle kinetics with amine-coupled antibody arrays
For multi-array printing of the CFM, two 96-well microplates
were prepared. The sample source plate contained 8 vertical wells
of each mAb prepared in sodium acetate (pH 5.0) from 20 mg/mL to
0.16 mg/mL in 2-fold serial dilutions, and the reagent plate con-
tained freshly prepared EDC/sulfo-NHS (400 mM/100 mM). After
the COOH-G SensEye chip in the CFM was primed with sodium
acetate (pH 5.0) running buffer, the sensor surface was activated
with the EDC/sulfo-NHS mixture for 5 min, followed by the
immobilization of mAbs directly onto the activated surface. During
this step, the mAb samples in the top half of the source plate were
delivered to the sensor using 48micro-channels, which allowed the
samples to cycle across the activated surfaces bidirectionally for10 min. The procedure was repeated for the remaining mAb sam-
ples in the bottom half of the source plate, resulting in the gener-
ation of a 10  8 array of mAb spots on the sensor surface. Two
vertical columns of wells contained only buffer, which served as
reference samples. The printed sensor chip was then docked into
the MX96 instrument and primed with the system's running buffer
(PBS [pH 7.4], 0.01% Tween-20) before quenching the surfaces with
1 M ethanolamine for 5 min. The binding interactions were
measured by cycling human PCSK9 prepared in the system running
buffer at 9 concentrations (0.39e100 nM in 2-fold serial dilutions)
across the mAb array surface. The cycling of each sequentially
injected sample was monitored for a 10-min association period
followed by a 45-min dissociation period, at a ﬂow rate of 40 ml/
min. Regeneration of the amine-coupled mAb surfaces using
glycine (pH 2.0 or pH 2.5) solutions was performed between each
binding cycle. These regeneration conditions were chosen based on
a preliminary experiment.
Single-cycle kinetics with Fc-captured antibody arrays
A SensEye COOH-G chip was ﬁrst docked into the MX96 in-
strument and primed with sodium acetate (pH 5.0) running buffer.
The sensor surface was activated by injecting EDC/sulfo-NHS
(400 mM/100 mM) for 5 min, then protein A/G prepared at
50 mg/mL in the running buffer was bidirectionally cycled across the
activated surface for 5 min. The sensor chip with the immobilized
protein A/G surface was then removed from the MX96 and inserted
into the CFM printer, which had been loaded with a 96-well mAb
source plate. The same plate layout and mAb concentrations
described above for the amine-coupled antibody array were used,
but the mAbs were prepared in the system running buffer, which
was PBS and 0.01% Tween-20. After the mAb samples were
captured through cycling across the protein A/G surface for 10 min,
the sensor chip was docked back into the MX96 instrument and
primed with the system running buffer. The binding interactions
were measured by cycling human PCSK9 prepared in the system
running buffer at 7 concentrations (1.56 nMe100 nM in 2-fold se-
rial dilutions). The cycling of each sequentially injected sample was
monitored as described in the previous section. No regeneration
was performed between sample injections.
Data analysis
Data processing and curve ﬁtting
All of the binding sensorgrams were collected at 25 C. Prior to
curve-ﬁtting analysis, the acquired data were processed as follows.
The Biacore T100 datawere double-referenced using reference ﬂow
cell 1 and preceding buffer blank subtraction using BiaEvaluation
(v.4.1) and the ProteOn XPR36 data were double-referenced using
channel inter-spots and a parallel in-line buffer blank subtraction
by the integrated ProteOn Manager software (v.3.1.0.6). Octet
RED384 data were referenced using a parallel buffer blank sub-
traction, and the baseline was aligned to the y-axis and smoothed
by a Savitzky-Golay ﬁlter in the data analysis software (v.9.0.0.4).
The IBIS MX96 data were ﬁrst inter-spot reference subtracted and
y-axis aligned using the IBIS SPRint software (v.6.15.2.1) and then
the calibrated data were exported to Scrubber (v.2.0c) for cropping,
aligning, and buffer injection referencing.
The processed binding curves from the four instruments were
all ﬁtted using the Langmuir model describing a 1:1 binding stoi-
chiometry. In the Biacore T100, “single mode” was used to perform
the ﬁtting of individual mAb surfaces, whereas “batch mode” with
“local” Rmax was used to perform the global ﬁtting of multiple mAb
surfaces. Similarly, in the ProteOn XPR36, “grouped” and “global”
modes were used along with “local” Rmax in the ﬁtting of single vs.
multiple surfaces. In the Octet RED384, “Rmax linked” was used to
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concentration, whereas “Rmax unlinked by sensor” was used to
perform the global ﬁtting on sensors coated with multiple mAb
concentrations. Both multi-cycle and single-cycle kinetic data from
the IBIS MX96 were analyzed using Scrubber (v.2.0c). After the
initial ﬁtting of kd in the absence of ka, kakd was selected to ﬁt with
kd being ﬁxed, and the ﬁt was then further reﬁned by ﬂoating the
kd. For single-cycle kinetic data, the injection start time was set as a
ﬂoating parameter to ﬁt the association proﬁles back to a theoret-
ical baseline origin. In all of the analyses, ka is the association rate
constant for the antibody-antigen binding reaction, kd is the
dissociation rate constant of the antibody-antigen complex, and KD
is the equilibrium dissociation constant deﬁned by kd/ka. The ac-
curacy of ﬁtting is described by Chi2 (Biacore T100, ProteOn XPR36,
and IBIS MX96) or X2 (Octet RED384), a parameter that represents
how well the results approximate those calculated from the model
used to analyze the data.Ligand surface activity
The binding activity of surface-bound mAbs toward human
PCSK9, namely the % ligand activity, was calculated using the
following equations:Fig. 1. Antibody capture levels on protein A/G immobilized surfaces in the Biacore T100 (A),
and low- (right) density surfaces are shown. The uniquely colored sensorgrams represent in
simultaneous capture of a particular mAb at the same concentration by 8 AHC sensor tips% Ligand Activity ¼ Experimental Rmax
Theoretical Rmax
 100%
where the theoretical Rmax was determined as follows:
Theoretical Rmax ¼ Analyte MWLigand MW  RL  SM
where MWwas the molecular weight of the ligand (mAb, 150 kDa)
and analyte (human PCSK9, 72.8 kDa), RL (ligand response) was the
amount of immobilized ligand in response units (RU), and SM was
the stoichiometry as deﬁned by the number of binding sites on the
ligand. Rearranging the equation provides the calculation of an
appropriate ligand density to aim for in the experiments:
RL ¼
Ligand MW
Analyte MW
 Rmax  1SM
For the kinetic binding measurements, Rmax was set at 50e200
RU.ProteOn XPR36 (B), and Octet RED384 (C). Results from high- (left), medium- (middle),
dividual mAbs in (A), six ligand channels from multiple capture cycles in (B), and the
in parallel in (C).
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To compare the analyzed results of the ten mAbs across the four
biosensor platforms, correlational (Spearman) analysis was per-
formed on the kinetic rate and equilibrium binding constants
relative to each other using GraphPad Prism (v6.05). The correla-
tion coefﬁcient (r) was determined along with the P-value, which
represents the signiﬁcance of the correlation.
Results
Ligand capture
In most cases, the mAbs were captured by protein A/G immo-
bilized on the sensor surface. Protein A/G is commonly used in our
laboratory as the capture reagent for IgGs due to its binding spec-
iﬁcity towards the IgG Fc region of various species and subclasses
[19]. Use of this protein therefore created a homogeneous orien-
tation of the Fab regions on the sensor surface. We also made use of
the anti-human IgG-Fc (AHC) sensor tips that were available for the
Octet RED384, which allowed for direct Fc-mediated coating of the
mAbs onto the sensor tips, without the need for surfaceFig. 2. CFM printing of antibody arrays and quantiﬁcation of RL levels of amine-coupled (A)
panels, where the grey areas enclosed by red squares signify the presence of antibody. The d
The printed antibody spots were quantiﬁed using the IBIS SPRint software by calculating the
antibodies are identiﬁed in the legend, and the number associated with each antibody corpreparation. To increase the rigor of the experiments, each mAb
was analyzed at a minimum of three surface densities. For the
Biacore T100 and ProteOn XPR36 experiments, we controlled the
antibody contact times and concentrations, respectively, to
generate a range of low- (~50 RU) to high-density (~250 RU) sur-
faces (Fig. 1A, B). These RL levels were chosen based on the standard
calculation of set Rmax values as described in Materials and
Methods. On the other hand, for the Octet RED384 and IBIS MX96
experiments, the mAb capture levels were achieved empirically by
using a series of 2-fold serially diluted antibodies at constant times.
While the low to high-density antibody capturing in the Octet
RED384 was monitored in real-time, resulting in 1.0e2.0 nm
wavelength shifts (Fig. 1C), the readout of mAb spots from the CFM
was visualized through a camera in the MX96 and quantiﬁed based
on the difference in bulk refractive index shifts between the amine-
coupled (Fig. 2A) or Fc-captured (Fig. 2B) antibodies and their
respective reference samples. As shown, a series of ten titrated
mAbs was analyzed on each chip. However, quantitative compari-
sons of the printed RL levels and the applied mAb concentrations
indicated that they were not positively correlated and suggested
that the samples were not printed consistently on the arrays.and Fc-captured (B) antibody surfaces. The printed antibody spots are shown in the left
arker inter-spots located between the active antibody spots were used for referencing.
difference in bulk shifts between the active and reference locations (right panels). The
responds to a number in the CFM array printout.
Fig. 3. Optimization of amine-coupled antibody surface regeneration in the IBIS MX96 using MgCl2 (A), 1/500 H3PO4 (B), 10 mM glycine-HCl, pH 2.5 (C), 10 mM glycine-HCl, pH 2.0
(D), and 10 mM glycine-HCl, pH 1.5 (E). Each condition was assessed with 3 binding-regeneration cycles followed by 2 blank buffer injection cycles. Uniquely colored sensorgrams
represent the mAbs indicated in the legend.
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formats, the results of the Fc-captured antibody arrays were more
inconsistent than those of the amine-coupled antibody arrays.Surface regeneration
To enable multiple binding cycle measurements within the
Table 1
Preservation of amine-coupled antibody surface activities in the IBIS MX96 after regeneration. The percentages were calculated based on the binding signals generated after
exposure to human PCSK9 following the third regeneration cycle in comparison to the initial binding signal prior to regeneration.
MgCl2 1/500 H3PO4 Glycine pH 2.5 Glycine pH 2.0 Glycine pH 1.5
mAb 1 100% 80% >100%a 100% 30%
mAb 2 60% 0% 100% 0% 50%
mAb 3 100% 80% >100%a 80% 50%
mAb 4 70% 80% 100% 80% 60%
mAb 5 90% 0% 100% 0% 50%
mAb 6 100% 80% >100%a 90% 40%
mAb 7 50% 10% 100% 80% 40%
mAb 8 80% 100% >100%a 100% 20%
mAb 9 70% 90% >100%a 100% 30%
mAb 10 50% 50% >100%a 80% 50%
a Incomplete regeneration.
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ProteOn XPR36 and the AHC sensor tips in the Octet RED384 were
regenerated with a standard acidic solution (10 mM Glycine HCl
[pH 1.5]). This regeneration condition successfully removed
antibody-antigen complexes from the surface and returned the
response signals to baseline. The use of both capturing reagents
generated consistent mAb surface densities throughout the study
(data not shown). The total number of binding-regeneration cycles
was 60 in the Biacore T100 and 5 in the ProteOn XPR36 and Octet
RED384. In the single-cycle kinetics experiment in the IBIS MX96,
the antigen-bound antibody array captured by Protein A/G was not
regenerated between each antigen injection.
To enable multi-cycle kinetic measurements using the IBIS
MX96, themAbswere directly immobilized onto the sensor through
amine coupling, and the mAb surfaces were regenerated between
antigen binding cycles. To identify regeneration conditions that
would allow for complete antigen removal without affecting the
antibody activity, an experiment was performed using different
regeneration solutions. Fig. 3 shows the recorded binding response
proﬁles of each mAb after one, two, and three regeneration cycles
with the indicated regeneration solutions. An increase in subse-
quent antigen binding signals indicated incomplete antigen
removal,whereas a decrease in subsequent antigen bindingor blank
injection signals indicated antibody surface deactivation. The re-
sults, which are summarized in Table 1, indicated that while none of
the regeneration solutions succeeded in preserving 100% antibody
activity for all of the mAbs, the glycine pH 2.0 solution worked the
best among all the regeneration solutions as 8 of the 10 mAbs
maintained >80% activity towards the antigen. The ranking is fol-
lowed by 1/500 H3PO4 and 3 M MgCl2 solutions, in which >80%
binding activities were maintained in 6 and 5 of the 10 mAbs,
respectively. Glycine pH 2.5 did not appear to remove all of the
bound antigen, whereas glycine pH 1.5 caused substantial deacti-
vation of the antibodies. Although glycine pH 2.0 was the preferred
solution, two of the antibodies (mAb 2 andmAb 5) were completely
deactivated after exposure to this solution. Thus, we decided to use
two regeneration conditions. Glycine pH 2.5 was used to regenerate
mAbs2and5,while glycinepH2.0wasused for the remainingmAbs.
Fig. 4 shows the comparison of the sensorgrams generated from
the single- and multi-cycle kinetic experiments using the IBIS
MX96. In the multi-cycle kinetic experiment, which included a
regeneration step, the baseline returned to zero between each of
the antigen binding steps, whereas in the single-cycle kinetic
experiment, the baselines increased due to the absence of regen-
eration steps.Ligand surface activity
Fig. 5 shows graphs of themAb capture levels plotted against theRmax values obtained from the ﬁtted binding curves. The plots
containing the Biacore T100-, ProteOn XPR36-, or Octet RED384-
generated data showed nearly linear correlations between the
mAb capture levels (RL) and the experimental Rmax values, as
illustrated by the high R2 values (close to 1). Using these linear
correlations, the activity of the ligand surface can be calculated
from the slope (Rmax/RL), obtained from the linear regression ﬁt,
and compared to the molecular weight ratio of the analyte and the
ligand. In this case, the molecular weight of human PCSK9 is
72.8 kDa and themolecular weight of themAb is 75 kDa per analyte
binding site, resulting in a mass ratio of 0.97. Once the slopes were
obtained, the activity of each of the 10 mAbs was calculated (see
Table 1 in Ref. [20]). In contrast to the positively correlated data
generated from the Biacore, ProteOn, and Octet biosensors, the data
from both the multi-cycle and single-cycle kinetic experiments
using the IBIS MX96 generated R2 values that were <0.5. In both
cases, the mAb surface activities were calculated by analyzing the
experimental Rmax/theoretical Rmax ratios as described in the Ma-
terials and Methods. Fig. 5F shows the calculated binding activities
of the mAb surfaces across the biosensor platforms. While the ac-
tivities associated with most of the systems were consistent, an
~10-fold lower activity was observed for the amine-coupled mAb
surfaces associated with the IBIS MX96, possibly due to antibody
inactivation or the generation of antibody orientations that were
not conducive to antigen binding.Background and blank subtraction
Prior to performing kinetic analysis on the binding curves, the
background signals were examined to ensure there was no non-
speciﬁc binding of the antigen to the reference surfaces. These
reference surfaces refer to those of non-active ﬂow cell (Biacore
T100), inter-spots on the array (ProteOn XPR36 and IBISMX96), and
AHC sensor tips (Octet RED384) that were immobilized with cap-
ture reagent without any ligand present. In IBIS MX96, the refer-
ence surfaces are those unmodiﬁed inter-spot regions (see Fig. 2,
left panels) where neither capture reagent nor ligand was spotted.
In addition to background inspection, the blank signals from buffer
injection over the active ligand surfaces were also examined to
ensure there was no signiﬁcant leaching of the ligand from the
sensor surface throughout the entire binding event. Inclusion of
both background and blank signals in data processing also allowed
for the monitoring/correction of buffer bulk effect and systematic
drift over time. Fig. 6 shows examples of the raw data collected on
both active and reference surfaces in each of the four instruments.
In all cases, there was no interaction of the antigen (up to 100 nM)
to the reference surfaces on the sensor chips during the association
phase (ﬂat line also observed in AHC sensor tips dipped directly
into antigen-containing wells, data not shown), validating that the
Fig. 4. MX96 binding sensorgram overlays from multi-cycle kinetic (A) and single-cycle kinetic (B) measurements. The antigen was injected at increasing concentrations (noted
above each injection) across the 10  8 antibody array created from the CFM. Regeneration was performed between antigen injections in (A), but was not performed during the
sequential antigen injections in (B).
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Fig. 5. Correlation of experimental Rmax and antibody surface levels in the Biacore T100 (A), ProteOn XPR36 (B), Octet RED384 (C), IBIS MX96, amine-coupled (D), and IBIS MX96, Fc-
captured (E). Each mAb is represented according to the legend. The Rmax was obtained by ﬁtting the binding curves using the 1:1 Langmuir kinetic model. The reported R2 values
(inserts) were generated by linear regression ﬁtting of the plots. The mean activities of the mAb surfaces and their standard deviations (error bars) are shown in (F).
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systematic drift, themaximal drift signal was observed to be ~10 RU
in Biacore T100 (Fig. 6A, right panels), ~30 RU in ProteOn XPR 36
(Fig. 6B, right panel), ~0.15 nm in Octet RED384 (Fig. 6C, right panel),
~10 RU on the amine-coupled surface in IBIS MX96 (Fig. 6D, leftpanel), and ~20 RU on the protein A/G surface in IBIS MX96 (Fig. 6D,
left panel). While the drifts in Octet RED384 and ProteOn XPR36
(the 100 nM curve) appeared to increase gradually with time in the
dissociation phase, those of Biacore T100 and IBIS MX96 were
relatively stable with ﬂuctuations scattering along the baseline. To
Fig. 6. Comparison of antigen binding and background/blank signals. Biacore T100 (A): antigen binding proﬁles (top left panel) and response signals (bottom left panel) over active
ﬂow cells 2e4, antigen binding proﬁles (top right panel) and response signals (bottom right panel) over reference ﬂow cell 1. ProteOn XPR36 (B): antigen binding proﬁles on active
channel L1 (left panel) and antigen binding proﬁles on reference inter-spots surrounding L1 (right panel). Octet RED384 (C): raw data from antibody-coated sensor tips dipped into
individual sample wells containing 100 nM antigen (left panel) and antibody-coated sensor tips dipped into individual samples wells containing 1xKB running buffer (right panel).
IBIS MX96 (D): raw data from mAb 1 on the amine-coupled (left panel) and protein A/G array surfaces (right panel), signals from the antibody spot are colored in black whereas that
of inter-spots are colored in green. The sensorgrams shown are the un-processed raw data recorded in real-time from each of the instruments.
Fig. 7. Antigen binding proﬁles of the captured antibodies and 1:1 kinetic model ﬁt overlays. The binding proﬁles were evaluated over high- (top panels), medium- (middle panels),
and low- (bottom panels) density surfaces in the Biacore T100. The antibody ID is noted right above the corresponding sensorgrams. The colored lines represent the recorded
binding response signals at different antigen concentrations, and the overlaid black lines represent the ﬁtted curves.
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were subtracted from the active sensorgrams to obtain the accurate
binding proﬁles prior to the kinetic analysis.Binding proﬁles and kinetic analysis
Figs. 7e10 show all of the processed data that were generated
using the four biosensor platforms, grouped by antibody ID and
sub-grouped by surface densities. On average, ﬁve antigen con-
centrations were used to provide evenly spaced binding curves
containing both low and high responses that represented 10e90%
ligand saturation. For comparison purposes, both the association
(10 min) and dissociation (45 min) times were kept constant across
the experiments; however, the experiments performed using OctetRED384 required shorter times (500 s association and 30 min
dissociation) due to sample evaporation over time. Relatively long
dissociation times were used to ensure the capture of signal decay
for mAbs that exhibited slow off-rates. Visual comparison of the
sensorgrams generated by the different instruments shows that
while a majority of the binding curves contained sufﬁcient signal
decay for accurate off-rate analysis, upward drift during the
dissociation phase was observed in some of the datasets generated
by the Octet RED384 (e.g. mAb 2, mAb 5, and mAb 9; Fig. 9),
resulting in higher end responses.
Overall, the binding proﬁles of the antibodies were similar
across the instruments. High reproducibility was also observed in
the binding data generated at varying surface densities using the
Biacore T100, ProteOn XPR36, and Octet RED384. In contrast, the
Fig. 8. Antigen binding proﬁles of the captured antibodies and 1:1 kinetic model ﬁt overlays. The binding proﬁles were evaluated over high- (top panels), medium- (middle panels),
and low- (bottom panels) density surfaces in the ProteOn XPR36. The antibody ID is noted right above the corresponding sensorgrams. The colored lines represent the recorded
binding response signals at different antigen concentrations, and the overlaid black lines represent the ﬁtted curves.
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which 71% of the Fc-captured and 61% of the amine-coupled spots
displayed acceptable binding signals for kinetic analysis, respec-
tively. These values were determined based on the combination of
three criteria assessed during the visual inspection of the raw data:
1. Insufﬁcient binding signal of generally <10 RU, such as mAb 1
sensorgram (1) in both Fig. 10A and B where no binding was
detected; 2. Spikes in the binding response curves, such as mAb 3
sensorgram (63) in Fig. 10A where a signiﬁcant amount of spikes
were introduced in the dissociation curve; and 3. Deviation of the
binding proﬁle compared to others within the same antibody, such
as mAb 8 sensorgram (93) in Fig. 10B where the dissociation curve
fell below 0 RU. With regard to the quality of the kinetic ﬁts, visual
inspection of the curves shows that most of the datasets returned
an overlay of the response data with the model ﬁt, indicating that
the antibody-antigen interactions ﬁt well to the chosen 1:1 kineticmodel. However, mAb 4 appeared to display biphasic behavior that
was observed on all four instruments. A low-quality ﬁt of the
response data was accompanied by a relatively high Chi2 (or X2)
value (see Tables 2 and 3 in Ref. [20]). Taken together, these ob-
servations suggested that the antigen binding of mAb 4 is more
complicated than that described by the simple 1:1 model.
To evaluate the variability of datasets generatedwithin the same
instrument, we compared kinetic rate constants generated using
different antibody densities. Fig. 11 shows plots of ka, kd, and KD at
different mAb surface densities. Strong linearity was observed for
all of the mAb rate constants generated using the Biacore T100 and
ProteOn XPR36, indicating high reproducibility across the multiple
surface densities. However, the rate constants generated by the
Octet RED384 were less linear, possibly due to ﬂuctuations in some
of the off-rates. The rate constants generated by the IBIS MX96
were also less linear, possibly due to ﬂuctuations in surface
Fig. 9. Antigen binding proﬁles of the captured antibodies and 1:1 kinetic model ﬁt overlays. The binding proﬁles were evaluated over high- (top panels), medium- (middle panels),
and low- (bottom panels) density surfaces in the Octet RED384. The antibody ID is noted right above the corresponding sensorgrams. The colored lines represent the recorded
binding response signals at different antigen concentrations, and the overlaid red lines represent the ﬁtted curves.
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observed across the multiple surfaces of the biosensors revealed
the following deviations: Biacore T100: 6 (±6)%; ProteOn XPR36: 13
(±6)%; Octet RED384: 21 (±19)%; IBIS MX96, Fc-captured mAbs: 19
(±11)%; and IBIS MX96, amine-coupled mAbs: 28 (±13)%.
Distribution and comparison of binding kinetics
Fig. 12 provides a visual summary of the distribution of the ki-
netic rate constants generated by the different biosensors (see Ta-
ble 4 in Ref. [20]). The afﬁnities of the ten mAbs were all between
0.01 and 10 nM, with the majority between 0.1 and 1 nM. Both the
association and dissociation rate constants spanned 1000-foldranges. Table 2 lists the calculated afﬁnities and rate constants of
each of the ten mAbs, along with their standard deviations. Even
though the rate constants associated with each of the antibodies
varied across the instruments, their rank order remained mostly
the same with two exceptions (Fig. 13). First, the ka rank order of
mAb 9 is lower than that of mAb 8 in ProteOn XPR36 (Fig.13A, green
line); and second, the kd rank order of mAb 8 is lower than that of
mAb 7 in Octet RED384 (Fig. 13B, red line). Additionally, the kd
values generated by the Octet RED384 (red line) were consistently
lower than those from the other instruments. Likewise, the ka
values from the single-kinetic analysis in the IBIS MX96 (orange
line) was lower in comparison to the others. To assess the general
correlation propensity of the reported rate constants among the
Fig. 10. Tiled view of the antigen binding proﬁles of the amine-coupled (A) and Fc-captured (B) antibodies in the 10  8 antibody array surfaces in the IBIS MX96. The antibody ID is
noted right above the corresponding sensorgrams. Each mAb is accompanied by 8 vertical panels that follow the array plate map in Fig. 2. The black lines represent the recorded
binding response signals, and the overlaid red lines represent the ﬁtted curves.
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results in Table 3 demonstrated that despite the two aforemen-
tioned exceptions, the kinetic rate and equilibrium binding con-
stants were positively correlated across the instruments. In general,
the individual rate constants determined on the instruments
showed strong correlation when analyzed in a pairwise manner.
One exception was the Octet RED384 e ProteOn XPR36 pair, which
exhibited only moderate correlation strength in comparison to theothers. Notably, the calculated afﬁnities (KD) showed slightly
weaker correlations than those of the individual rate constants.
Discussion
This study was conducted to provide data-driven recommen-
dations for the use of the four biosensor platforms by assessing
their ability to provide quality kinetic data. Unlike previous
Table 2
Kinetic rates and equilibrium binding constants and their standard deviations determined from the four biosensor platforms.
ka (M1 s1) ka (% CV) kd (s1) kd (% CV) KD (nM) KD (% CV)
mAb 1 11.7 (7.8)  105 67 4.89 (4.18)  105 86 0.052 (0.05) 92
mAb 2 1.53 (0.28)  105 19 1.30 (1.54)  105 118 0.092 (0.12) 128
mAb 3 11.4 (8.3)  105 72 27.6 (11.0)  105 40 0.333 (0.20) 61
mAb 4 3.61 (1.6)  105 45 20.1 (12.3)  105 61 0.659 (0.54) 83
mAb 5 0.59 (0.21)  105 35 3.46 (2.50)  105 72 0.663 (0.46) 70
mAb 6 1.19 (0.78)  105 65 7.21 (3.83)  105 53 0.894 (0.64) 72
mAb 7 1.29 (0.53)  105 41 16.4 (5.63)  105 34 1.57 (1.02) 65
mAb 8 4.02 (2.23)  105 55 22.8 (10.7)  105 47 0.768 (0.68) 88
mAb 9 4.20 (2.13)  105 51 6.67 (4.3)  105 64 0.197 (0.16) 82
mAb 10 1.20 (0.49)  105 41 12.5 (7.64)  105 61 1.27 (0.80) 63
Average ka %CV 49 Average kd %CV 64 Average KD %CV 80
Table 3
Correlation of kinetic rates and equilibrium binding constants among the biosensor platforms. Positive correlation coefﬁcients (r) indicate positive correlations and r values
close to 1 indicate stronger correlations. The correlation strength is deﬁned as follows: very strong (0.8e1.0, dark green), strong (0.60e0.79, light green), and moderate
(0.40e0.59, yellow).
Correlation 
coefficient (r)
ka correlation kd correlation KD correlation
Biacore 
T100
ProteOn 
XPR36
Octet 
RED384
IBIS MX96 
(amine-
coupled)
IBIS MX96 
(Fc-
capture)
Biacore 
T100
ProteOn 
XPR36
Octet 
RED384
IBIS MX96 
(amine-
coupled)
IBIS MX96 
(Fc-
capture)
Biacore 
T100
ProteOn 
XPR36
Octet 
RED384
IBIS 
MX96 
(amine-
coupled)
IBIS MX96 
(Fc-
capture)
Biacore T100 --- 0.966**** 0.821**** 0.895**** 0.962*** --- 0.911**** 0.927**** 0.974**** 0.864**** --- 0.869**** 0.706** 0.858**** 0.833****
ProteOn 
XPR36 0.966**** --- 0.775*** 0.858**** 0.932*** 0.911**** --- 0.787*** 0.860**** 0.886**** 0.869**** --- 0.470* 0.776*** 0.701**
Octet 
RED384 0.821**** 0.775*** --- 0.862**** 0.792*** 0.927**** 0.787*** --- 0.921**** 0.858**** 0.706** 0.470* --- 0.722** 0.841****
IBIS MX96 
(amine-
coupled) 
0.895**** 0.858**** 0.862**** --- 0.919*** 0.974**** 0.860**** 0.921**** --- 0.824**** 0.858**** 0.776*** 0.722** --- 0.756**
IBIS MX96 
(Fc-capture) 0.962**** 0.932**** 0.792*** 0.919**** --- 0.864*** 0.886**** 0.858**** 0.824**** --- 0.833**** 0.701** 0.841**** 0.756** ---
*  P>0.05 
**  0.01<P<0.05 
*** 0.005<P<0.01 
****P<0.005 
D. Yang et al. / Analytical Biochemistry 508 (2016) 78e9692benchmark studies that involved the analysis of only single
antibody-antigen binding pairs, and recruited a large number of
participants who used the same biosensor technology with the
same assay format [8], or different biosensor technologies with
variable assay formats [17], our study expanded the number of
analyzed binding interactions (10 mAbs against the same antigen),
while limiting external factors that could inﬂuence data variability.
For example, we limited the number of hands-on researchers to
two, performed the experiments on all four biosensor platforms
simultaneously, and used the same high-quality reagents
throughout the study.
Our results showed that the instruments with continuous ﬂow
ﬂuidics (the Biacore T100, ProteOn XPR36, and IBISMX96) provided
high-quality data for resolving high-afﬁnity interactions
(0.1e1.0 nM) with slow dissociation rates. Upward drifts in the
dissociation curves were observed in some of the datasets gathered
from the Octet RED384 BLI platform that were likely due to sample
evaporation over time in the microplate, which is a well-knownprimary limitation of the system. Re-binding of the antigen in
each sample well was also a possibility, but according to the
manufacturer, this can be minimized by the orbital agitation of the
microplate at high speed. Nevertheless, these two potential limi-
tations have presented uncertainties in analyzing high-afﬁnity
binding interactions of our antibodies as compared to the ﬂuidic
platforms. Further analysis showed that when the Octet RED384-
generated rate constants were excluded from the global calcula-
tions, an ~20% improvement in both the average kd and KD standard
deviations (from 64% to 47% and 80%e61%, respectively) was
observed, while the ka deviation remained the same, further sup-
porting the notion that the Octet RED384's inherent limitation
renders the analysis of slow dissociation proﬁles inaccurate.
We also found inconsistencies in the generation of the antibody
array by the CFM in the IBIS MX96. For accurate kinetic measure-
ments, the amount of ligand on the biosensor surface is a critical
parameter that needs to be controlled to ensure that the binding
responses are not disturbed by secondary factors such as mass
Fig. 11. Correlation of kinetic rate constants and antibody surface densities in the Biacore T100 (A), ProteOn XPR36 (B), Octet RED384 (C), IBIS MX96, amine-coupled (D), and IBIS
MX96, Fc-captured (E). The ka, kd, and KD calculated from the individual ﬁtted curves are shown in the top, middle, and bottom sub-panels, respectively. The mAbs are identiﬁed in
the legend.
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Fig. 12. Two-dimensional isoafﬁnity kinetic plot of rate constants grouped by antibody.
The dashed diagonals depict the equilibrium binding constants and are shown to help
with the visualization of the afﬁnity distribution.
Fig. 13. Comparison of the kinetic rates and equilibrium binding constants generated
by the biosensor platforms. The ka, kd, and KD for each antibody, as calculated from
Figs. 6e9, are shown in (A), (B), and (C), respectively. The instruments are represented
as follows: Biacore T100 (blue), ProteOn XPR36 (green), Octet RED384 (red), IBIS MX96,
amine-coupled (purple), and IBIS MX96, Fc-captured (orange).
D. Yang et al. / Analytical Biochemistry 508 (2016) 78e9694transfer or steric hindrance [21]. However, the lack of consistent
ligand immobilization combined with inefﬁcient array printing in
this instrument, resulted in reduced data reproducibility. In addi-
tion, our observation that some of the binding response levels were
relatively high suggested that we could not rule out the possibility
of surface complications in the inﬂuence of rate constant accuracy.
We also found that certain aspects of this system were suboptimal
for the purpose of high-resolution kinetic constant determinations.
For example, the separation of the CFM device from the MX96
detector was inconvenient for performing multi-cycle kinetic ex-
periments. Not only did this setup require the ligands, in this case
our 10 mAbs, to be directly immobilized onto the sensor surface
through amine coupling, but it also required optimal regeneration
conditions to be determined in advance, which had extended the
total experimental time. Given the known issue of surface hetero-
geneity from the amine coupling and regeneration process to yield
variable results, the low ligand activity and high KD inconsistency
associated with this setup were somewhat expected.
As an alternative approach, we adapted a single-cycle kinetics
setup [22], which does not require regeneration, to the IBIS MX96.
The elimination of surface regeneration also allowed us to incor-
porate the Fc-capture method into this experiment. Multiple
studies have shown that the single-cycle kinetic approach yields
results that are comparable to that of traditional approaches with
added advantages in reagent and time savings [22e24]. Using this
approach, we found that the calculated afﬁnities and off-rates were
consistent with those generated using the multi-cycle kinetic
approach. In particular, excluding the KD and kd values generated
from this approach from the global calculations had no effect on the
standard deviations. However, the single-cycle kinetic-generated ka
values were lower than the values produced by the other biosensor
systems in 6 of the 10 mAbs. Further analysis showed an ~10%
improvement in the global ka deviation (from 49% to 39%) when the
single-cycle kinetics ka value was excluded from the calculation.
The decreased ka was probably due to the depletion of ligand-
binding sites along with increasing steric hindrance as the
antibody-antigen complexes accumulated on the surface. Regard-
less, the mAb afﬁnities were not signiﬁcantly affected.
Overall, we found that the Biacore T100 generated the most
consistent data, followed by the ProteOn XPR36, and the Octet
RED384 and IBIS MX96, which generated comparable but lower
quality data. However, the Biacore T100 platform also ranked
lowest in sample throughput. This limitation was overcome by the
other three platforms, which expanded the number of interactionsmeasured in a single binding cycle to 36 (ProteOn XPR36), 16 (Octet
RED384), and 96 (IBIS MX96). Since our experiments incorporated
long dissociation times, there were no signiﬁcant differences in the
experimental times of these three platforms, and in all cases the
D. Yang et al. / Analytical Biochemistry 508 (2016) 78e96 95experiments were completed in one day. On the other hand, the
Biacore T100 experiments required 3 days to complete, despite the
walk-away automation in data acquisition after the setup. With
respect to user hands-on time, a unique feature of the Octet plat-
form is the availability of pre-coated sensors for immediate use,
resulting in the reduction of preparation time by eliminating the
need for ligand immobilization. On the other hand, the sensor chip
initiation and pre-conditioning steps in the ProteOn XPR36 adds
more hands-on time when compared to both Biacore and Octet
platforms. Similarly, the microarray printing for the IBIS MX96
platform is also a relatively attentive and time-consuming proce-
dure. Even though the preparation time can be offset by the anal-
ysis of ten mAbs simultaneously, we found that we beneﬁted from
inserting multiple mAb concentration spots on the array to coun-
teract the printing inconsistency. With regard to the material
consumption, the total amounts of samples consumed on each of
the four biosensor platforms was roughly equivalent in our exper-
iments which involved multiple ligand surfaces and analyte in-
jections. Even though the Octet platform allows for the materials to
be recovered, most of our samples had evaporated from the open
microplate after the overnight run.
The ability of antibodies to bind their targets with high afﬁnity
and speciﬁcity has made them very attractive therapeutic modal-
ities. However, characterizing high-afﬁnity antibody-antigen in-
teractions can be technically challenging when the instruments'
detection limits are reached. Although the majority of the calcu-
lated rate constants fall below the typical uppermost association
detection limit (1  107 in Biacore T100 [25], 3  106 in ProteOn
XPR36 [26], 1  107 in Octet RED384 [27] and 5  106 in IBIS MX96
[28], in the unit of M1 s1), as well as above the typical lowest
dissociation detection limit (1 105 in Biacore T100 [25], 1 106
in ProteOn XPR36 [26], 1  106 in Octet RED384 [27] and 2  106
in IBIS MX96 [28], in the unit of s1) of respective systems ac-
cording to the manufacturers' speciﬁcations, a number of them
approach these limits with <5-fold differences (see Tables 5 in
Ref. [20]). As the binding interactions approach these typical limits,
it is instinctive for researchers to raise concern about the accuracy
of the analyzed kinetic parameters. However, ﬁndings from our
studies showed that working limits should be considered with
caution as they also depend upon other important factors such as
the inherent limitations of the systems and the experimental
conditions. For example, although the described Biacore T100
dissociation limit is an order of magnitude higher than the others,
the high quality data generated from our head-to-head comparison
study suggested that the working limit was at the least comparable
with the ProteOn XPR36, and better than both Octet RED384 and
IBIS MX96. On the contrary, the aforementioned limitations in
Octet RED384 presented challenges in producing accurate dissoci-
ation curves despite expectations for resolving slow off-rates based
on its speciﬁcations. Similarly, the underlying limitation of the
experimental designs involving amine-coupled and non-
regenerative protein A/G surfaces in IBIS MX96 compromised the
accuracy of the on-rates, regardless whether the instrument was
capable of producing data within the expected limits.
Taking all the data obtained from the four biosensor platforms
together, our calculations of the rate constants on these antibodies
with sub-nanomolar antigen afﬁnity revealed the following de-
viations: 49 (±17)% in ka, 64 (±24)% in kd, and 80 (±20)% in KD. Even
though our results indicated an expected trade-off between data
accuracy/consistency and sample throughput, the rank order of the
acquired kinetic rate constants was highly consistent across the
instruments. Despite certain limitations in instrumentation that
impacted data accuracy, these platforms generated binding data
that ﬁt the simple 1:1 molecular interaction model, and were
capable of identifying those proﬁles that deviated from the model.Deviations in the kinetic binding data that we observed resulted
from differences in the methodologies of the platforms. Each
platform has its own advantages and disadvantages, the latter of
whichmay ormay not be tolerated, depending on the experimental
goals of the researcher. For example, even though the Octet RED384
is limited in its ability to resolve slow dissociation interactions, it is
highly ﬂexiblewith regard to sensor choice and assay conﬁguration,
in addition to ease of operation. Although the throughput of the
IBIS MX96 is orders of magnitude higher than that of the other
biosensors, the robustness in its array printing requires substantial
improvement to fully utilize its throughput advantage. Regardless,
it is one of the few instruments (along with the Octet) that are
equipped for effective combinatorial epitope binning analysis and
has the potential to become an extremely versatile tool if its per-
formance can be improved. With the discontinuation of the Pro-
teOn XPR36 in the near future, it is unclear whether its high quality
performance can be maintained given the unknown availability of
future instrument support. Taken together, for studies that require
sensitive and reliable detection, either Biacore T100 or ProteOn
XPR36 is best suited.Whereas for studies inwhich speed is a critical
factor and large number of samples (i.e. in the hundreds) are
involved, either Octet RED384 or IBIS MX96 is preferred as both
offer the throughput and efﬁciency needed for rapid data acquisi-
tion. For the purpose of candidate ranking, assuming the number of
samples and the amount of materials are not limiting factors, any of
these instruments may be used, as our results demonstrated that
the obtained rate constants differentiated the antibodies compa-
rably irrespective of which instrument was used.
In summary, our unbiased results may not only help new
biosensor users determine the best instrument for their research
purposes, thereby maximizing the value of their investment, but
may also provide additional insights to current biosensor users
regarding the systematic factors that inﬂuence data reliability, to
enable the appropriate selection of biosensor instruments for their
studies.
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